The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Statin-induced myopathy: a review and update
Abstract
INTRODUCTION: Statin-induced myopathy is an important cause of statin intolerance and the most common cause of statin discontinuation. Observational studies estimate that 10 - 15% of statin users develop statin-related muscle side effects ranging from mild myalgia to more severe muscle symptoms with significant CPK elevations. AREAS COVERED: This article reviews the epidemiology, clinical features, risk factors and mechanisms of statin-induced myopathy and provides an evidence-based algorithm for managing patients with statin myopathy. EXPERT OPINION: There are multiple risk factors for statin-induced myopathy that are both patient-related (age, genetics, co-morbidities) and drug-related (statin metabolism via the CYP system, drug-drug interactions and statin drug transport). Management options for statin-intolerant patients include statin switching, especially to low-dose, non-daily doses of long-acting statins, such as rosuvastatin and atorvastatin, and other non-statin lipid-lowering agents, such as ezetimibe and colesevelam, and possibly red yeast rice. In conclusion, statin-induced myopathy is a significant clinical problem that contributes considerably to statin therapy discontinuation. However, there exist multiple and effective management options for statin intolerant patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043 · cited 2×
“Multiple studies have shown an association between SLCO1B1 polymorphisms and statin myopathy [40,41].”
BackgroundMethodThompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Writing Committee Members:, Pasternak, R. C., Smith, S. C., Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., & Lenfant, C. (2002) · Circulation · doi:10.1161/01.cir.0000032466.44170.44 · Cited by 1,088
The safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
Kotseva, K., Wood, D., Backer, G. D., Bacquer, D. D., Pyörälä, K., Keil, U., & EUROASPIRE Study Group (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283294b1d · Cited by 812 · cited 1×
“A recent European study estimated that 20% of patients with coronary heart disease do not use statins [3].”
BackgroundStatin Safety: A Systematic Review
Law, M., & Rudnicka, A. R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.010 · Cited by 808
A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)
Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W.-P., & Kirchgessner, T. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37161 · Cited by 641
Cerivastatin and Reports of Fatal Rhabdomyolysis
Staffa, J. A., Chang, J., & Green, L. (2002) · New England Journal of Medicine · doi:10.1056/nejm200202143460721 · Cited by 626
Cited by
Guiding Principles for the Care of Older Adults with Multimorbidity: An Approach for Clinicians
American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.04188.x · Cited by 660
An assessment by the statin muscle safety task force: 2014 update
Rosenson, R. S., Baker, S. K., Jacobson, T. A., Kopecky, S. L., & Parker, B. A. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.03.004 · Cited by 485
Self-citationSafety and efficacy of statin therapy
Adhyaru, B. B., & Jacobson, T. A. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0098-5 · Cited by 424
Self-citationBanach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al-Rasadi, K., Aronow, W. S., Athyros, V., Djuric, D. M., Ezhov, M. V., et al. (2015) · Archives of Medical Science · doi:10.5114/aoms.2015.49807 · Cited by 378
Wilke, R. A., Ramsey, L. B., Johnson, S. G., Maxwell, W. D., McLeod, H. L., Voora, D., Krauss, R. M., Roden, D. M., Feng, Q., Cooper-DeHoff, R. M., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.57 · Cited by 332
American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.04187.x · Cited by 308
Huang, R., Xia, M., Sakamuru, S., Zhao, J., Shahane, S. A., Attene-Ramos, M., Zhao, T., Austin, C. P., & Simeonov, A. (2016) · Nature Communications · doi:10.1038/ncomms10425 · Cited by 259
Coenzyme Q10 supplementation: Efficacy, safety, and formulation challenges
Arenas‐Jal, M., Suñé‐Negre, J. M., & García‐Montoya, E. (2020) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12539 · Cited by 239
Resistance and intolerance to statins
Reiner, Ž. (2014) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.05.009 · Cited by 225
Rett syndrome: a neurological disorder with metabolic components
Kyle, S. M., Vashi, N., & Justice, M. J. (2018) · Open Biology · doi:10.1098/rsob.170216 · Cited by 213
Effects of Coenzyme Q10 on Statin-Induced Myopathy
Banach, M., Serban, C., Sahebkar, A., Ursoniu, S., Rysz, J., Muntner, P., Toth, P. P., Jones, S. R., Rizzo, M., Glasser, S. P., et al. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.08.021 · Cited by 198
Elsby, R., Hilgendorf, C., & Fenner, K. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.163 · Cited by 198
Banach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al-Rasadi, K., Aronow, W. S., Athyros, V., Djuric, D. M., Ezhov, M. V., et al. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1039980 · Cited by 162
Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation
Seidah, N. G., Poirier, S., Denis, M., Parker, R., Miao, B., Mapelli, C., Prat, A., Wassef, H., Davignon, J., Hajjar, K. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041865 · Cited by 117
Discontinuation of statin therapy due to muscular side effects: A survey in real life
Rosenbaum, D., Dallongeville, J., Sabouret, P., & Bruckert, E. (2013) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2012.04.012 · Cited by 111
Statin myotoxicity: a review of genetic susceptibility factors
Needham, M., & Mastaglia, F. L. (2014) · Neuromuscular Disorders · doi:10.1016/j.nmd.2013.09.011 · Cited by 108
Nutraceuticals for the treatment of hypercholesterolemia
Mannarino, M. R., Ministrini, S., & Pirro, M. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.06.008 · Cited by 92
Muntean, D. M., Thompson, P. D., Catapano, A. L., Stasiolek, M., Fabis, J., Muntner, P., Serban, M.-C., & Banach, M. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.09.001 · Cited by 82
Pisciotta, L., Bellocchio, A., & Bertolini, S. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-123 · Cited by 79
Curcumin: an effective adjunct in patients with statin-associated muscle symptoms?
Sahebkar, A., Saboni, N., Pirro, M., & Banach, M. (2017) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12140 · Cited by 72
Vaughan, R. A., Garcia-Smith, R., Bisoffi, M., Conn, C. A., & Trujillo, K. A. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.04.009 · Cited by 58
Marcheggiani, F., Cirilli, I., Orlando, P., Silvestri, S., Vogelsang, A., Knott, A., Blatt, T., Weise, J. M., & Tiano, L. (2019) · Aging · doi:10.18632/aging.101926 · Cited by 53
Meek, C., Wierzbicki, A. S., Jewkes, C., Twomey, P. J., Crook, M. A., Jones, A., & Viljoen, A. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.657302 · Cited by 52
“7 (78) Blood pressure, mmHg (% hypertensive) 138 19/79 11 (74) 136 19/79 10 (73) Smoking, current/previous/never, (%) 32/90/132 (13/35/52) 19/86/110 (9/40/51) Secondary prevention of CVD (%) 102 (31) 88 (41) Coronary heart disease (%) 86 (26) 60 (28) Stroke/TIA (%) 12 (4) 12 (6) Diabetes (%) 48 (15) 30 (14) Familial h…”
Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy
Wiklund, O., Pirazzi, C., & Romeo, S. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0397-8 · Cited by 45
Lipid-lowering effects of oleanolic acid in hyperlipidemic patients
LUO, H.-Q., SHEN, J., CHEN, C.-P., MA, X., LIN, C., OUYANG, Q., XUAN, C.-X., LIU, J., SUN, H.-B., & LIU, J. (2018) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(18)30065-7 · Cited by 44
Primary prevention of cardiovascular disease with statins in the elderly
Reiner, Ž. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0420-6 · Cited by 38
Vaughan, R. A., Mermier, C. M., Bisoffi, M., Trujillo, K. A., & Conn, C. A. (2014) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-013-0301-4 · Cited by 34
Rechallenging Statin Therapy in Veterans With Statin-Induced Myopathy Post Vitamin D Replenishment
Kang, J. H., Nguyen, Q.-N., Mutka, J., & Le, Q. A. (2017) · Journal of Pharmacy Practice · doi:10.1177/0897190016674407 · Cited by 28
Andrade, C. (2013) · Bipolar Disorders · doi:10.1111/bdi.12130 · Cited by 18
Ren, Q., Tan, Y., Zhang, G., Dai, Y., Yang, L., Wu, Y., He, H., & Chen, J. (2025) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70021 · Cited by 9
Metadata
- Authors
- Abd, T. T., & Jacobson, T. A.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa Healthcare
- Published
- 2011-02-23
- Volume
- 10
- Issue
- 3
- Pages
- 373-387
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2136466059
- Cited by
- 322
- References
- 98
- FWCI
- 24.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.